$CHRS
Coherus BioSciences Inc

2023 Q4 Form 10-Q Financial Statement

#000155837023017779 Filed on November 06, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $91.52M $74.57M $45.40M
YoY Change 101.81% 64.25% -44.97%
Cost Of Revenue $84.57M $32.70M $35.23M
YoY Change 495.46% -7.18% 65.57%
Gross Profit $6.957M $41.87M $10.17M
YoY Change -77.67% 311.81% -83.4%
Gross Profit Margin 7.6% 56.14% 22.39%
Selling, General & Admin $49.49M $48.22M $44.83M
YoY Change -7.7% 7.57% 12.29%
% of Gross Profit 711.43% 115.19% 440.99%
Research & Development $26.37M $25.65M $45.81M
YoY Change -9.14% -44.01% -15.3%
% of Gross Profit 379.01% 61.26% 450.6%
Depreciation & Amortization $1.091M $800.0K $995.0K
YoY Change 3.9% -19.6% 11.55%
% of Gross Profit 15.68% 1.91% 9.79%
Operating Expenses $75.86M $73.87M $90.64M
YoY Change -8.21% -18.5% -3.59%
Operating Profit -$68.91M -$32.01M -$80.45M
YoY Change 33.81% -60.22% 145.37%
Interest Expense -$10.62M $10.27M $7.540M
YoY Change 13.15% 36.18% 30.65%
% of Operating Profit
Other Income/Expense, Net -$129.0K $2.253M $1.339M
YoY Change -106.42% 68.26% 4363.33%
Pretax Income -$79.65M -$40.02M -$86.65M
YoY Change 35.3% -53.81% 124.9%
Income Tax $0.00 -$380.0K $0.00
% Of Pretax Income
Net Earnings -$79.65M -$39.64M -$86.65M
YoY Change 35.3% -54.25% 124.9%
Net Earnings / Revenue -87.03% -53.16% -190.86%
Basic Earnings Per Share -$0.41 -$1.11
Diluted Earnings Per Share -$0.71 -$0.41 -$1.11
COMMON SHARES
Basic Shares Outstanding 111.4M 94.47M 77.72M
Diluted Shares Outstanding 97.74M 77.75M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $117.7M $131.1M $286.8M
YoY Change -38.57% -54.29% -38.81%
Cash & Equivalents $102.9M $80.26M $286.8M
Short-Term Investments $14.86M $50.80M $0.00
Other Short-Term Assets $34.76M $30.00M $42.57M
YoY Change -14.81% -29.52% 40.0%
Inventory $130.1M $66.78M $27.72M
Prepaid Expenses
Receivables $260.5M $216.5M $91.19M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $508.4M $444.4M $448.3M
YoY Change 33.35% -0.87% -33.4%
LONG-TERM ASSETS
Property, Plant & Equipment $5.119M $6.069M $9.571M
YoY Change -41.52% -36.59% 12.53%
Goodwill $943.0K $943.0K
YoY Change 4.78%
Intangibles $71.67M
YoY Change 1108.45%
Long-Term Investments
YoY Change
Other Assets $49.56M $7.823M $9.627M
YoY Change 471.77% -18.74% -6.19%
Total Long-Term Assets $121.2M $139.4M $102.6M
YoY Change 21.7% 35.84% 49.42%
TOTAL ASSETS
Total Short-Term Assets $508.4M $444.4M $448.3M
Total Long-Term Assets $121.2M $139.4M $102.6M
Total Assets $629.6M $583.8M $550.9M
YoY Change 30.94% 5.97% -25.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $35.22M $37.09M $9.917M
YoY Change 205.56% 274.02% -78.3%
Accrued Expenses $169.6M $67.11M $85.99M
YoY Change 238.63% -21.95% 87.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $721.0K
YoY Change -39.46%
Total Short-Term Liabilities $169.6M $239.7M $171.3M
YoY Change 22.32% 39.89% -46.52%
LONG-TERM LIABILITIES
Long-Term Debt $473.4M $472.8M $470.5M
YoY Change 0.19% 0.49% 66.9%
Other Long-Term Liabilities $180.0M $3.513M $102.0K
YoY Change 5092.24% 3344.12% -86.4%
Total Long-Term Liabilities $653.4M $3.513M $102.0K
YoY Change 18745.8% 3344.12% -86.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $169.6M $239.7M $171.3M
Total Long-Term Liabilities $653.4M $3.513M $102.0K
Total Liabilities $823.0M $717.4M $648.0M
YoY Change 33.12% 10.7% 6.07%
SHAREHOLDERS EQUITY
Retained Earnings -$1.580B -$1.500B -$1.283B
YoY Change 17.73% 16.93% 27.75%
Common Stock $11.00K $11.00K $7.000K
YoY Change 37.5% 57.14% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$193.4M -$133.6M -$97.13M
YoY Change
Total Liabilities & Shareholders Equity $629.6M $583.8M $550.9M
YoY Change 30.94% 5.97% -25.73%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$79.65M -$39.64M -$86.65M
YoY Change 35.3% -54.25% 124.9%
Depreciation, Depletion And Amortization $1.091M $800.0K $995.0K
YoY Change 3.9% -19.6% 11.55%
Cash From Operating Activities -$12.94M -$54.30M -$37.09M
YoY Change -87.06% 46.4% -370.51%
INVESTING ACTIVITIES
Capital Expenditures -$14.00K $0.00 -$457.0K
YoY Change -116.09% -100.0% 75.1%
Acquisitions
YoY Change
Other Investing Activities $34.95M $50.60M $0.00
YoY Change -126.92% -100.0%
Cash From Investing Activities $35.20M $50.50M -$457.0K
YoY Change -127.1% -11150.33% -102.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 366.0K 11.10M 48.87M
YoY Change -94.45% -77.29% 4338.42%
NET CHANGE
Cash From Operating Activities -12.94M -54.30M -37.09M
Cash From Investing Activities 35.20M 50.50M -457.0K
Cash From Financing Activities 366.0K 11.10M 48.87M
Net Change In Cash 22.63M 7.300M 11.32M
YoY Change -110.14% -35.52% -63.25%
FREE CASH FLOW
Cash From Operating Activities -$12.94M -$54.30M -$37.09M
Capital Expenditures -$14.00K $0.00 -$457.0K
Free Cash Flow -$12.92M -$54.30M -$36.63M
YoY Change -87.08% 48.23% -362.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001512762
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78851516
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109113046
CY2023Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36721
dei Entity Registrant Name
EntityRegistrantName
Coherus BioSciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3615821
dei Entity Address Address Line1
EntityAddressAddressLine1
333 Twin Dolphin Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94065
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
649-3530
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
CHRS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
111364152
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80259000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63547000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
50818000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
128134000
CY2023Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
216511000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
109964000
CY2023Q3 us-gaap Inventory Net
InventoryNet
66783000
CY2022Q4 us-gaap Inventory Net
InventoryNet
38791000
CY2023Q3 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
13772000
CY2022Q4 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
17880000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16222000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
22918000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
444365000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
381234000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6069000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8754000
CY2023Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
79002000
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
76260000
CY2023Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
46524000
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
5931000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7823000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8668000
CY2023Q3 us-gaap Assets
Assets
583783000
CY2022Q4 us-gaap Assets
Assets
480847000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
37092000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11526000
CY2023Q3 chrs Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
117369000
CY2022Q4 chrs Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
54461000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
18084000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22610000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67114000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
50097000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
239659000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
138694000
CY2023Q3 chrs Term Loans Payable Noncurrent
TermLoansPayableNoncurrent
246217000
CY2022Q4 chrs Term Loans Payable Noncurrent
TermLoansPayableNoncurrent
245483000
CY2023Q3 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
226557000
CY2022Q4 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
225575000
CY2023Q3 chrs Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
1436000
CY2022Q4 chrs Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
5046000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3513000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3467000
CY2023Q3 us-gaap Liabilities
Liabilities
717382000
CY2022Q4 us-gaap Liabilities
Liabilities
618265000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109113046
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78851516
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
11000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1366502000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1204431000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-265000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-249000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1499847000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1341608000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-133599000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-137418000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
583783000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
480847000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
74568000
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
45424000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
165720000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
165690000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
32703000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
35234000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
74425000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
55881000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25647000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45808000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
83068000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
170336000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
48224000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
44831000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
142521000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
144860000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
106574000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
125873000
us-gaap Costs And Expenses
CostsAndExpenses
300014000
us-gaap Costs And Expenses
CostsAndExpenses
371077000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-32006000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-80449000
us-gaap Operating Income Loss
OperatingIncomeLoss
-134294000
us-gaap Operating Income Loss
OperatingIncomeLoss
-205387000
CY2023Q3 us-gaap Interest Expense
InterestExpense
10268000
CY2022Q3 us-gaap Interest Expense
InterestExpense
7540000
us-gaap Interest Expense
InterestExpense
29923000
us-gaap Interest Expense
InterestExpense
23089000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6222000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2253000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1339000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5598000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1814000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40021000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-86650000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-158619000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-232884000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-380000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-380000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-39641000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-86650000
us-gaap Net Income Loss
NetIncomeLoss
-158239000
us-gaap Net Income Loss
NetIncomeLoss
-232884000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.00
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97738509
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97738509
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77746895
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77746895
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88277936
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88277936
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77520244
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77520244
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-39641000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-86650000
us-gaap Profit Loss
ProfitLoss
-158239000
us-gaap Profit Loss
ProfitLoss
-232884000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
32000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-15000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-39609000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-86650000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-158255000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-232884000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-137418000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-75729000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
103000
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2781000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12288000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-29000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-196507000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-42869000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
305000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1337000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10034000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-19000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-174764000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-39641000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
53000
CY2023Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
58541000
CY2023Q3 chrs Stock Issued During Period Value Accelerated Vesting Of Equity Awards
StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards
1053000
CY2023Q3 chrs Stock Issued During Period Value Taxes Paid Related To Net Share Settlement Of Equity Awards
StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards
347000
CY2023Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
115000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10152000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
32000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-133599000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
97726000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-96084000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
544000
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2658000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13037000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
12563000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-50150000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
642000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1655000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13935000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-22629000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-86650000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
79000
CY2022Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
321000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12388000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-97133000
us-gaap Profit Loss
ProfitLoss
-158239000
us-gaap Profit Loss
ProfitLoss
-232884000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2728000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2649000
us-gaap Share Based Compensation
ShareBasedCompensation
32312000
us-gaap Share Based Compensation
ShareBasedCompensation
39011000
us-gaap Inventory Write Down
InventoryWriteDown
4369000
us-gaap Inventory Write Down
InventoryWriteDown
26000000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2835000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1812000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
5631000
chrs Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
2016000
chrs Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
1854000
chrs Upfront License Fee Payments Related To License And Collaboration Arrangements
UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements
35000000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6222000
chrs Other Noncash Adjustments
OtherNoncashAdjustments
-915000
chrs Other Noncash Adjustments
OtherNoncashAdjustments
-10000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
106626000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-31849000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
34941000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
37556000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-4108000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
6967000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-10702000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12509000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
24545000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-6149000
chrs Increase Decrease In Accrued Rebates Fees And Reserve
IncreaseDecreaseInAccruedRebatesFeesAndReserve
60602000
chrs Increase Decrease In Accrued Rebates Fees And Reserve
IncreaseDecreaseInAccruedRebatesFeesAndReserve
-25006000
chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-8810000
chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-623000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
7225000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
32317000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-161947000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-141171000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
252000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1952000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
769000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
19507000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
108148000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
13282000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
6997000
chrs Upfront And Milestone Based License Fee Payments Investing Activities
UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities
35000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
109437000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-36952000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
240679000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
170000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
631000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1337000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1655000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3261000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3621000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
109000000
us-gaap Repayments Of Debt
RepaymentsOfDebt
81750000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-835000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-861000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
69234000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
47733000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16724000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-130390000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63987000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
417635000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80711000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
287245000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Accounting estimates and judgements are inherently uncertain and therefore actual results could differ from these estimates.</p>
CY2023Q3 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
167892000
CY2021Q4 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
109723000
chrs Reserve For Sales Discounts And Allowances Constitute Variable Consideration
ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
426962000
chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
-7300000
chrs Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration
PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
446720000
CY2022Q3 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
82665000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63547000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
417195000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
440000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
440000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63987000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
417635000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80259000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
286805000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
452000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
440000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80711000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
287245000
CY2023Q3 chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
1100000
CY2022Q3 chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
-1400000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
74568000
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
45424000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
165720000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
165690000
CY2022Q4 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
100503000
chrs Reserve For Sales Discounts And Allowances Constitute Variable Consideration
ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
539609000
chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
4634000
chrs Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration
PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
476854000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
113253000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
47000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
113207000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
191623000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
43000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
21000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
191645000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
14
chrs Impairment Recognized On Securities
ImpairmentRecognizedOnSecurities
0
chrs Contractual Maturities Of Available For Sale Debt Securities Remaining Maturity
ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity
P1Y
chrs Remaining Contractual Maturities Of Available For Sale Debt Securities Acquisition
RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition
P10M
chrs Investments Made During Period Marketable Securities
InvestmentsMadeDuringPeriodMarketableSecurities
0
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
11326000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
10262000
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
106608000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
86712000
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
27851000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
18077000
CY2023Q3 us-gaap Inventory Gross
InventoryGross
145785000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
115051000
CY2022Q3 us-gaap Inventory Write Down
InventoryWriteDown
26000000.0
CY2023Q3 us-gaap Inventory Net
InventoryNet
66783000
CY2022Q4 us-gaap Inventory Net
InventoryNet
38791000
CY2023Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
79002000
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
76260000
CY2023Q3 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
145785000
CY2022Q4 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
115051000
CY2023Q3 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
13800000
CY2023Q3 chrs Prepayments Made To Cmo For Manufacturing Services
PrepaymentsMadeToCmoForManufacturingServices
12400000
CY2023Q3 chrs Prepayments Made To Cmo For Other Research And Development Pipeline Program
PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram
1400000
CY2022Q4 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
17900000
CY2022Q4 chrs Prepayments Made To Cmo For Manufacturing Services
PrepaymentsMadeToCmoForManufacturingServices
13000000.0
CY2022Q4 chrs Prepayments Made To Cmo For Other Research And Development Pipeline Program
PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram
4900000
CY2023Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
26935000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
28911000
CY2023Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
20866000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
20157000
CY2023Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
6069000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
8754000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2500000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
900000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2600000
CY2023Q3 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
3200000
CY2022Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
3500000
CY2023Q3 us-gaap Goodwill
Goodwill
943000
CY2022Q4 us-gaap Goodwill
Goodwill
943000
CY2023Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
28859000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2620000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
16722000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2368000
CY2023Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
46524000
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
5931000
CY2023Q3 chrs Finite Lived Intangible Asset Expected Amortization For Each Of Five Succeeding Fiscal Years
FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears
1300000
CY2023Q3 chrs Accrued Commercial And Research And Development Manufacturing Liabilities Current
AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent
17057000
CY2022Q4 chrs Accrued Commercial And Research And Development Manufacturing Liabilities Current
AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent
21774000
CY2023Q3 chrs Accrued Co Development Costs Payable To Junshi Biosciences
AccruedCoDevelopmentCostsPayableToJunshiBiosciences
1293000
CY2022Q4 chrs Accrued Co Development Costs Payable To Junshi Biosciences
AccruedCoDevelopmentCostsPayableToJunshiBiosciences
8356000
CY2023Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
30557000
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5015000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9698000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10634000
CY2023Q3 chrs Lease Liabilities Operating And Financing
LeaseLiabilitiesOperatingAndFinancing
4469000
CY2022Q4 chrs Lease Liabilities Operating And Financing
LeaseLiabilitiesOperatingAndFinancing
4318000
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
4040000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67114000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
50097000
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1352000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
102000
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1102000
CY2023Q3 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
1059000
CY2022Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
3365000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3513000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3467000
CY2022Q1 chrs Collaboration Agreement Option Exercise Fee Per Program
CollaborationAgreementOptionExerciseFeePerProgram
35000000.0
CY2023Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
CY2023Q3 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
27800000
CY2022Q4 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
2900000
CY2020Q2 us-gaap Share Price
SharePrice
14.82
CY2023Q3 us-gaap Share Price
SharePrice
3.74
CY2023Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
15117000
CY2023Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
54929000
CY2023Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
11050000
CY2023Q3 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
839000
CY2023Q3 us-gaap Purchase Obligation
PurchaseObligation
81935000
CY2022Q2 us-gaap Product Liability Contingency Loss Exposure Not Accrued Best Estimate
ProductLiabilityContingencyLossExposureNotAccruedBestEstimate
14000000.0
CY2023Q3 chrs Number Of Derivative Instrument Held For Trading Or Speculative Purpose
NumberOfDerivativeInstrumentHeldForTradingOrSpeculativePurpose
0
CY2023Q3 us-gaap Derivative Assets
DerivativeAssets
0
CY2023Q3 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
82000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38642448
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36783266
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38300024
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38052771
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-23-017779-index-headers.html Edgar Link pending
0001558370-23-017779-index.html Edgar Link pending
0001558370-23-017779.txt Edgar Link pending
0001558370-23-017779-xbrl.zip Edgar Link pending
chrs-20230930.xsd Edgar Link pending
chrs-20230930x10q.htm Edgar Link pending
chrs-20230930xex10d1.htm Edgar Link pending
chrs-20230930xex10d2.htm Edgar Link pending
chrs-20230930xex31d1.htm Edgar Link pending
chrs-20230930xex31d2.htm Edgar Link pending
chrs-20230930xex32d1.htm Edgar Link pending
chrs-20230930_cal.xml Edgar Link unprocessable
chrs-20230930_def.xml Edgar Link unprocessable
chrs-20230930x10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
chrs-20230930_pre.xml Edgar Link unprocessable
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
chrs-20230930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable